Department of Anaesthesiology, Technical University of Munich, Munich, Germany.
Department of Anaesthesiology, Surgical Services and Intensive Care, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Lancet Respir Med. 2019 Feb;7(2):129-140. doi: 10.1016/S2213-2600(18)30294-7. Epub 2018 Sep 14.
Results from retrospective studies suggest that use of neuromuscular blocking agents during general anaesthesia might be linked to postoperative pulmonary complications. We therefore aimed to assess whether the use of neuromuscular blocking agents is associated with postoperative pulmonary complications.
We did a multicentre, prospective observational cohort study. Patients were recruited from 211 hospitals in 28 European countries. We included patients (aged ≥18 years) who received general anaesthesia for any in-hospital procedure except cardiac surgery. Patient characteristics, surgical and anaesthetic details, and chart review at discharge were prospectively collected over 2 weeks. Additionally, each patient underwent postoperative physical examination within 3 days of surgery to check for adverse pulmonary events. The study outcome was the incidence of postoperative pulmonary complications from the end of surgery up to postoperative day 28. Logistic regression analyses were adjusted for surgical factors and patients' preoperative physical status, providing adjusted odds ratios (OR) and adjusted absolute risk reduction (ARR). This study is registered with ClinicalTrials.gov, number NCT01865513.
Between June 16, 2014, and April 29, 2015, data from 22 803 patients were collected. The use of neuromuscular blocking agents was associated with an increased incidence of postoperative pulmonary complications in patients who had undergone general anaesthesia (1658 [7·6%] of 21 694); OR 1·86, 95% CI 1·53-2·26; ARR -4·4%, 95% CI -5·5 to -3·2). Only 2·3% of high-risk surgical patients and those with adverse respiratory profiles were anaesthetised without neuromuscular blocking agents. The use of neuromuscular monitoring (OR 1·31, 95% CI 1·15-1·49; ARR -2·6%, 95% CI -3·9 to -1·4) and the administration of reversal agents (1·23, 1·07-1·41; -1·9%, -3·2 to -0·7) were not associated with a decreased risk of postoperative pulmonary complications. Neither the choice of sugammadex instead of neostigmine for reversal (OR 1·03, 95% CI 0·85-1·25; ARR -0·3%, 95% CI -2·4 to 1·5) nor extubation at a train-of-four ratio of 0·9 or more (1·03, 0·82-1·31; -0·4%, -3·5 to 2·2) was associated with better pulmonary outcomes.
We showed that the use of neuromuscular blocking drugs in general anaesthesia is associated with an increased risk of postoperative pulmonary complications. Anaesthetists must balance the potential benefits of neuromuscular blockade against the increased risk of postoperative pulmonary complications.
European Society of Anaesthesiology.
回顾性研究结果表明,全身麻醉中使用神经肌肉阻滞剂可能与术后肺部并发症有关。因此,我们旨在评估神经肌肉阻滞剂的使用是否与术后肺部并发症有关。
我们进行了一项多中心、前瞻性观察队列研究。研究对象为来自欧洲 28 个国家的 211 家医院的 21 岁及以上接受全身麻醉进行任何院内手术(不包括心脏手术)的患者。在 2 周内前瞻性收集患者特征、手术和麻醉细节以及出院时的病历记录。此外,每位患者在术后 3 天内接受术后体格检查,以检查肺部不良事件。研究结果是从手术结束到术后第 28 天的术后肺部并发症发生率。使用 logistic 回归分析调整了手术因素和患者术前身体状况,提供了调整后的优势比(OR)和调整后的绝对风险降低(ARR)。本研究在 ClinicalTrials.gov 注册,编号为 NCT01865513。
2014 年 6 月 16 日至 2015 年 4 月 29 日期间,共收集了 22803 例患者的数据。全身麻醉中使用神经肌肉阻滞剂与术后肺部并发症的发生率增加有关(21694 例患者中有 1658 例[7.6%];OR 1.86,95%CI 1.53-2.26;ARR -4.4%,95%CI -5.5 至 -3.2)。只有 2.3%的高风险手术患者和有不良呼吸特征的患者在没有使用神经肌肉阻滞剂的情况下接受了麻醉。使用神经肌肉监测(OR 1.31,95%CI 1.15-1.49;ARR -2.6%,95%CI -3.9 至 -1.4)和使用逆转剂(1.23,1.07-1.41;ARR -1.9%,-3.2 至 -0.7)与降低术后肺部并发症风险无关。使用舒更葡糖钠而非新斯的明逆转(OR 1.03,95%CI 0.85-1.25;ARR -0.3%,95%CI -2.4 至 1.5)或在四成比为 0.9 或更高时拔管(1.03,0.82-1.31;ARR -0.4%,-3.5 至 2.2)均与更好的肺部结局无关。
我们表明,全身麻醉中使用神经肌肉阻滞剂与术后肺部并发症的风险增加有关。麻醉师必须权衡神经肌肉阻滞的潜在益处与术后肺部并发症增加的风险。
欧洲麻醉学会。